Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H17Cl2FN4O4S.C7H8O3S |
| Molecular Weight | 635.512 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)S(O)(=O)=O.OC2=C(C(Cl)=CC=C2NC(=O)NC3=CC=CC(F)=C3Cl)S(=O)(=O)N4CCNCC4
InChI
InChIKey=CJAUWWGOABMMJX-UHFFFAOYSA-N
InChI=1S/C17H17Cl2FN4O4S.C7H8O3S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24;1-6-2-4-7(5-3-6)11(8,9)10/h1-5,21,25H,6-9H2,(H2,22,23,26);2-5H,1H3,(H,8,9,10)
| Molecular Formula | C17H17Cl2FN4O4S |
| Molecular Weight | 463.311 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C7H8O3S |
| Molecular Weight | 172.202 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Elubrixin (SB-656933) is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment. In preclinical studies, the compound was shown to inhibit CXCL1-induced CD11b up-regulation on PMNs in an in vitro whole blood assay and to be active in in vivo rodent inhalation challenge models of airway inflammation that used endotoxin and ozone to induce airway neutrophilia. Elubrixin was being developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease, cystic fibrosis and ulcerative colitis. Elubrixin was withdrawn from the Phase II trial due to the lack of efficacy.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inflammatory bowel disease therapies discontinued between 2009 and 2014. | 2015 |
|
| International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. | 2014 |
|
| Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. | 2013-05 |
|
| SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. | 2011-08 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:55:06 GMT 2025
by
admin
on
Mon Mar 31 20:55:06 GMT 2025
|
| Record UNII |
13FVR7WD4P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2178579
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
YY-69
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
300000044512
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
13FVR7WD4P
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
DTXSID60242106
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
23634419
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
960495-43-6
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY | |||
|
C166455
Created by
admin on Mon Mar 31 20:55:06 GMT 2025 , Edited by admin on Mon Mar 31 20:55:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |